Tatva Chintan Pharma Chem Limited (TATVA.NS)
INR 861.95
(-0.2%)
INR 861.95
(-0.2%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 947.86 Million | 277.83 Million | 203.78 Million | 243.19 Million | 253.12 Million | 73.56 Million |
| Net Income | 303.54 Million | 447.79 Million | 1.04 Billion | 606.96 Million | 475.97 Million | 273.93 Million |
| Depreciation & Amortization | 256.05 Million | 95.55 Million | 81.8 Million | 67.32 Million | 47.93 Million | 40.18 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 357.33 Million | -284.15 Million | -753.71 Million | -377.76 Million | -226.44 Million | -216.59 Million |
| Other non-cash items | 179.39 Million | 18.64 Million | -165.52 Million | -53.33 Million | -44.34 Million | -23.96 Million |
| Investing Cash Flow | -1.23 Billion | -1.01 Billion | -1.96 Billion | -210.06 Million | -401.8 Million | -167.7 Million |
| Investments in PPE | -1.28 Billion | -2.03 Billion | -891.57 Million | -209.7 Million | -481.72 Million | -97.86 Million |
| Acquisitions | 1.55 Million | 680 Thousand | 780 Thousand | 190 Thousand | 270 Thousand | 72.03 Million |
| Investment purchases | -99 Million | -967.42 Million | -1.12 Billion | -190 Thousand | -270 Thousand | -77.34 Million |
| Sales/Maturities of investments | 144.46 Million | 966.74 Million | 1.12 Billion | 2.49 Million | 74.48 Million | 5.31 Million |
| Other Investing Activities | 79.75 Million | 1.01 Billion | -1.07 Billion | -2.85 Million | 5.44 Million | -69.84 Million |
| Financing Cash Flow | 370.51 Million | 377.95 Million | 2.34 Billion | -88.01 Million | 99.52 Million | 173.99 Million |
| Debt repayment | -1.54 Billion | -139.37 Million | -135.28 Million | -183.99 Million | -87.15 Million | -66.29 Million |
| Dividends payments | -46.78 Million | -44.33 Million | - | -40.18 Million | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 1.96 Billion | - | 2.11 Billion | - | - | - |
| Other Financing Activities | -690 Thousand | 561.65 Million | 373.88 Million | 136.16 Million | 186.67 Million | 240.28 Million |
| Accounts receivables | 112.48 Million | -314.4 Million | 322.99 Million | -419.3 Million | -83.13 Million | -125.16 Million |
| Accounts payables | 153.85 Million | -126.56 Million | -30.63 Million | 158.64 Million | 94.77 Million | -25.68 Million |
| Inventory | 97.32 Million | 74.59 Million | -979.39 Million | -84.63 Million | -279.64 Million | -67.72 Million |
| Other working capital | -6.32 Million | 82.22 Million | -66.68 Million | -32.47 Million | 41.56 Million | 1.97 Million |
| Cash at beginning of period | 309.11 Million | 630.17 Million | 44.81 Million | 108.29 Million | 157.45 Million | 77.6 Million |
| Cash at end of period | 382.92 Million | 273.66 Million | 630.17 Million | 53.41 Million | 108.29 Million | 157.45 Million |
| Capital Expenditure | -1.28 Billion | -2.03 Billion | -891.57 Million | -209.7 Million | -481.72 Million | -97.86 Million |
| Effect of forex changes on cash | -840 Thousand | -860 Thousand | -180 Thousand | -8.6 Million | - | - |
| Net cash flow / Change in cash | 73.81 Million | -356.51 Million | 585.36 Million | -54.88 Million | -49.16 Million | 79.85 Million |
| Free Cash Flow | -337.29 Million | -1.75 Billion | -687.79 Million | 33.49 Million | -228.6 Million | -24.3 Million |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 52.09 Million | 303.54 Million | 96.14 Million | 34.55 Million | 77.81 Million | 95.04 Million |
| Depreciation & Amortization | - | 256.05 Million | - | 65.83 Million | 67.77 Million | 60.12 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | 357.33 Million | - | - | - | - |
| Other non-cash items | -52.09 Million | 179.39 Million | -96.14 Million | -34.55 Million | -77.81 Million | -95.04 Million |
| Investing Cash Flow | - | -1.23 Billion | - | - | - | - |
| Investments in PPE | - | -1.28 Billion | - | - | - | - |
| Acquisitions | - | 1.55 Million | - | - | - | - |
| Investment purchases | - | -99 Million | - | - | - | - |
| Sales/Maturities of investments | - | 144.46 Million | - | - | - | - |
| Other Investing Activities | - | 79.75 Million | - | - | - | - |
| Financing Cash Flow | - | 370.51 Million | - | - | - | - |
| Debt repayment | - | -1.54 Billion | - | - | - | - |
| Dividends payments | - | -46.78 Million | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 1.96 Billion | - | - | - | - |
| Other Financing Activities | - | -690 Thousand | - | - | - | - |
| Accounts receivables | - | 112.48 Million | - | - | - | - |
| Accounts payables | - | 153.85 Million | - | - | - | - |
| Inventory | - | 97.32 Million | - | - | - | - |
| Other working capital | - | -6.32 Million | - | - | - | - |
| Cash at beginning of period | - | 309.11 Million | - | 1.43 Billion | 1.3 Billion | 309.11 Million |
| Cash at end of period | - | 382.92 Million | - | 1.56 Billion | 1.43 Billion | 429.35 Million |
| Capital Expenditure | - | -1.28 Billion | - | - | - | - |
| Effect of forex changes on cash | - | -840 Thousand | - | - | - | - |
| Net cash flow / Change in cash | - | 73.81 Million | - | 131.66 Million | 135.54 Million | 120.24 Million |
| Free Cash Flow | - | -337.29 Million | - | 131.66 Million | 135.54 Million | 120.24 Million |
600127
000893
001229
IMCC
OBIIF
ARRY